For example, Ali et al. demonstrated that FASN mediates EGFR palmitoylation in EGFR-mutated non-small cell lung cancer cells and regulates the sensitivity of tyrosine kinase inhibitors [42]. Here, EGFR is linked to non-small cell lung carcinoma.